News
BCRX
10.45
-2.52%
-0.27
BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus
Simply Wall St · 15h ago
Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?
Simply Wall St · 3d ago
BioCryst Pharmaceuticals Price Target Raised to $14.00/Share From $13.00 by RBC Capital
Dow Jones · 5d ago
BioCryst Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 5d ago
RBC Capital Maintains Outperform on BioCryst Pharma, Raises Price Target to $14
Benzinga · 5d ago
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal
TipRanks · 5d ago
Eupraxia Pharma adds Robert Bazemore, Amy Pott, Helen Thackray to board
PUBT · 5d ago
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
NASDAQ · 5d ago
Weekly Report: what happened at BCRX last week (0629-0703)?
Weekly Report · 6d ago
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery, Is The Stock Still Undervalued?
Simply Wall St · 07/05 10:25
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal
NASDAQ · 07/02 14:09
BioCryst grants new hires stock options for 33,950 shares at $9.65 each
PUBT · 07/02 11:00
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/02 11:00
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story
Simply Wall St · 07/01 22:39
BioCryst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/30 14:45
BioCryst Pharmaceuticals Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 06/30 14:45
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target
Benzinga · 06/30 14:35
BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
TipRanks · 06/30 13:35
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 06/30 13:04
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)
TipRanks · 06/30 12:20
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.